Enlivex (ENLV) Net Income (2013 - 2025)
Enlivex (ENLV) posted quarterly Net Income of -$4.9 million for Q4 2025, down 119.68% year-over-year from $24.9 million in Q4 2024, and up 61.92% quarter-over-quarter from -$12.8 million in Q3 2025.
Enlivex (ENLV) Net Income (2013 - 2025) Analysis & Trends
Enlivex's Net Income history runs 13 years deep, the most recent figure standing at -$4.9 million for Q4 2025.
- In Q4 2025, Net Income fell 119.68% year-over-year to -$4.9 million; the TTM figure through Dec 2025 stood at -$12.4 million (down 182.7% YoY), while the FY2025 annual figure was $1.2 billion, up 8129.17% from the prior year.
- Net Income for Q4 2025 stood at -$4.9 million, up from -$12.8 million in the prior quarter.
- The five-year high for Net Income was $26.4 million in Q2 2022, with the low at -$49.0 million in Q4 2023.
- The 5-year median for Net Income is -$3.3 million (2021), against an average of -$3.6 million.
- The sharpest annual moves came in 2022 and 2025: Net Income slumped 1326.9% in 2022, then soared 183.33% in 2025.
- Enlivex's Net Income stood at -$24.2 million in 2021, then jumped by 70.29% to -$7.2 million in 2022, then tumbled by 582.17% to -$49.0 million in 2023, then jumped by 150.68% to $24.9 million in 2024, then slumped by 119.68% to -$4.9 million in 2025.
- Business Quant data shows ENLV's Net Income at -$4.9 million in Q4 2025, -$12.8 million in Q3 2025, and $8.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | -5.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.89 Mn |
| Sep 30, 2025 | -12.85 Mn |
| Jun 30, 2025 | 8.77 Mn |
| Mar 31, 2025 | -3.45 Mn |
| Dec 31, 2024 | 24.85 Mn |
| Sep 30, 2024 | -17.07 Mn |
| Jun 30, 2024 | 3.10 Mn |
| Mar 31, 2024 | 4.14 Mn |
| Dec 31, 2023 | -49.04 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 21.23 Mn |
| Mar 31, 2023 | -7.22 Mn |
| Dec 31, 2022 | -7.19 Mn |
| Sep 30, 2022 | -42.01 Mn |
| Jun 30, 2022 | 26.36 Mn |
| Mar 31, 2022 | -8.23 Mn |
| Dec 31, 2021 | -24.20 Mn |
| Sep 30, 2021 | 3.42 Mn |
| Jun 30, 2021 | 9.51 Mn |
| Mar 31, 2021 | -3.20 Mn |